Cancer Pain Market 2020 Size, Share, Industry Insight, Top Key Players BioDelivery Sciences International, Inc., Daiichi Sankyo Co., Ltd., Grnenthal Pharma GmbH

The global cancer pain market size accounted for $5.53 Billion in 2018 and is projected to reach $7.54 billion by 2025, registering a CAGR of 4.5% during the forecast period.

Increase in incidence of cancer worldwide, surge in healthcare expenditure, and advancements in technology drive the growth in the market. However, adverse effects related to usage of drugs for cancer pain management restrain the market growth. On the other hand, surge in number of pipeline drugs create new opportunities in the industry.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5123

The global cancer pain market is divided on the basis of type, disease indication, and region. Based on type, the market is segmented into opioids, non-opioids, and nerve blockers. The opioids segment held the largest share in 2018, contributing more than half of the market and is expected to continue its dominance throughout the study period. In addition, the segment is estimated to register the fastest CAGR of 5.0% during the forecast period.

On the basis of disease indication, the market is divided into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. The lung cancer segment dominated the market, accounting for more than one-fifth of the market. Moreover, the segment is projected to witness the fastest CAGR of 6.1% through 2025.

Lung cancer segment to maintain its leadership status during the forecast period

Based on disease indication, the lung cancer segment held the major share in 2018, contributing for nearly one-fourth of the total market share, and is expected to maintain its leadership status during the forecast period. In addition, this segment would grow at the fastest CAGR of 6.1% from 2018 to 2025. This is a lucrative segment, owing to high prevalence of lung cancer and increase in the usage of cancer pain killers to get relief, upsurge in cigarette smoking population, and availability of advanced diagnostic techniques.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/5123

Opioids segment to continue its dominant position throughout the forecast period

Based on drug type, the opioids segment contributed the highest market share in 2018, accounting for nearly three-fifths of the total share, and is expected to continue its dominant position throughout the forecast period. Moreover, this segment is expected to grow at the highest CAGR of 5.0% from 2018 to 2025. This is attributed to rise in adoption of opioids for management of cancer pain and their nature of being the FDA-approved first line drugs for treating moderate or severe chronic cancer pain. The report also analyzes non-opioids and nerve blockers segments. The report also analyzes colorectal cancer, breast cancer, prostate cancer, blood cancer, and others.

Frontrunner of the industry

Leading market players analyzed in the research Aoxing Pharmaceutical Company, Inc., Daiichi Sankyo Co., Ltd., BioDelivery Sciences International, Inc., Hisamitsu Pharmaceutical Co., Inc., Grunenthal Pharma GmbH & Co. KG, Mundipharma International Limited, Insys Therapeutics, Inc., Pfizer Inc., Orexo AB, and Teva Pharmaceutical Industries Limited.

North America to maintain its highest share by 2025

Based on region, North America accounted for the major market share in 2018, accounting for more than two-fifths of the total market share. This region is expected to maintain its highest share during the forecast period. This is due to rapid increase in prevalence of different types of cancers, advancements in technologies, ease in availability of pain therapeutics, and availability of premiere chemotherapy treatments. On the other hand, Asia-Pacific would register the fastest growth rate with a CAGR of 5.4% from 2018 to 2025, owing to rise in prevalence of cancer in China, Japan, and India, increase in early screening of cancer, and surge in availability of pain therapeutics.

Read More: https://www.alliedmarketresearch.com/cancer-pain-market

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Life Science Market: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.